Background-Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events.
Introduction
The Systolic Blood Pressure Intervention Trial (SPRINT), sponsored by the National Institutes of Health (NIH), was a study of blood pressure (BP) control in persons without diabetes mellitus at increased risk of developing cardiovascular disease (CVD). 1 The relative hazard of the primary composite end point in SPRINT, which included myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or death from cardiovascular causes, was significantly lower in the intensive arm (goal systolic BP [SBP] <120 mm Hg) compared with the standard arm (goal SBP <140 mm Hg). 2 In addition, all-cause mortality was significantly lower in the intensive BP-lowering arm of the trial.
The frequency of serious adverse events (SAEs) in SPRINT was not significantly different between the two arms of the trial. The SAEs that were anticipated to be higher in the intensive arm of the trial were a priori ascertained by the clinical sites and by the SPRINT Safety Officer. Conditions of interest that were more frequent in the intensive arm included hypotension, syncope, electrolyte abnormalities and acute kidney injury (AKI), typically noted in association with hospitalization. 2 The goals of our detailed examination of AKI in SPRINT were to 1) identify predictors of AKI resulting in either a hospitalization or emergency room visit; 2) adjudicate each of the reported AKI events; 3) determine severity of, and recovery from, these events; and 4) explore effect modification of intensive versus standard BP lowering on AKI within each of the six predefined participant subgroups. Changes in kidney function that were noted based on SPRINT clinic laboratory results that did not result in a hospitalization or emergency room visit will be described in two other SPRINT studies. 2a,2b consent. Participants from 102 clinical sites were randomly assigned to a target goal SBP of <120 mm Hg (intensive arm, n=4678) or <140 mm Hg (standard arm, n=4683). The design, eligibility, full trial protocol, sample size calculations and interim analysis and stopping rules have been previously reported. 1, 2 The SPRINT trial cohort included participants 50 years or older with SBP ≥130 mm Hg, without a history of diabetes or stroke, with an increased risk of cardiovascular events, defined by one or more of the following: clinical or subclinical CVD other than stroke; chronic kidney disease (CKD), excluding polycystic kidney disease; a 10-year risk of CVD of 15% or greater on the basis of the Framingham risk score; or an age of 75 years or older. Persons with diabetes mellitus, polycystic kidney disease, screening urine protein level of >1 g/day or equivalent, symptomatic heart failure, ejection fraction <35% or stroke were excluded from the trial. Participant enrollment into SPRINT occurred November 2010 to March 2013.
Study Outcomes
Demographic data were collected at baseline, including self-reported race and ethnicity. Six pre-specified subgroups of interest for all outcomes included the following: CVD at baseline (yes vs. no), CKD at baseline (yes vs. no), sex, race (black vs. nonblack), age (<75 vs. ≥75 years), and tertiles of baseline SBP (≤132 mm Hg, >132 to <145 mm Hg, and ≥145 mm Hg). The presence of CKD at randomization was defined as an estimated glomerular filtration rate (eGFR) of 20-59 ml/min/1.73 m 2 using the isotope-dilution mass spectrometry (IDMS)traceable 4-variable MDRD (Modification of Diet in Renal Disease) Study equation; this definition defined the CKD cohort in SPRINT. 3 Clinical and laboratory data were obtained at baseline and every three months thereafter. Serum creatinine concentration was measured in a central laboratory by an enzymatic procedure using a Roche analyzer and was IDMS-traceable for calibration. Urine albumin was measured by an immunoturbidometric method using a Roche analyzer. Urine albumin was quantified along with urine creatinine in random spot urine specimens, with the urine albumin-creatinine ratio (ACR, in mg/g) used to account for urine concentration. AKI was defined using a modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria 4 incorporating only serum creatinine concentrations to assess for the stage of AKI (ignoring the component of urine output, which was not uniformly measured). These modified KDIGO criteria include the following AKI stages and serum creatinine definitions: stage 1, increase ≥0.3 mg/dL or increase of 1.5 to 2.0-fold from baseline; stage 2, increase >2.0-to 3.0-fold from baseline; stage 3, increase >3.0-fold from baseline or ≥4.0 mg/dL with an acute increase of 0.5 mg/dL or need for renal replacement therapy.
At quarterly study visits, a structured interview was used to query participants about hospitalizations in the prior three months as well as specific outcomes of interest, such as initiation of dialysis. 2 The SAEs were also identified between visits if study staff were informed of them by participant report, electronic medical record notification, or other mechanism. The SAEs were defined as events that were fatal or life threatening, resulted in significant or persistent disability, required or prolonged a hospitalization, or medical events that the investigator judged to be a significant hazard or harm to the participant and required medical or surgical intervention to prevent hospitalization, death or persistent disability. For selected SAEs, including AKI (either as the primary reason for hospitalization or as a part of the hospitalization), clinic staff were required to obtain medical records of the event for review by the medical safety officer, including Emergency Department (ED) notes for ED visits and the admission history and physical and discharge summary for hospitalizations. The medical safety team at the Coordinating Center reviewed the medical records from hospitalizations and ED visits and from SAE reports, and the team recorded AKI if it was noted on admission or occurred during a hospitalization or ED visit and was reported in the hospital discharge summary as a primary or main secondary diagnosis. If the discharge summary did not list AKI as a primary or secondary diagnosis, the record was not reviewed to determine whether an AKI event may have occurred but was not listed explicitly. In some cases, these records included all laboratory creatinine values obtained during the admission while in other cases only those creatinine values recorded in the discharge summary and/or the admission note and/or progress notes were used to ascertain the occurrence and severity of AKI. The Medical Dictionary for Regulatory Activities (MedDRA) was used to classify the safety events. Coding was performed at the Coordinating Center and up to three codes were assigned to each safety event.
All SAEs and ED visits classified as involving an AKI event by the safety team were reviewed in a blinded fashion by two nephrologists or physician experts in outcomes adjudication to determine the baseline and peak creatinine values, the modified KDIGO stage of AKI, what was the underlying primary cause of the AKI, and whether it was thought that SPRINT study participation caused or contributed to the event. Baseline creatinine was defined as the most recent SPRINT outpatient creatinine value prior to the date of the AKI event. Disagreements regarding the baseline and peak creatinine values, stage of AKI or whether SPRINT study participation caused or contributed to the event were resolved by a single third adjudicator (M.V.R.). After blinded adjudication, 54 of 402 events were not thought to represent AKI by modified KDIGO criteria. Therefore, the remainder of this study reports on the 348 events adjudicated as AKI.
Recovery of kidney function was determined by comparing the peak recorded serum creatinine value with the lowest outpatient SPRINT creatinine value obtained in the subsequent 365 days. Recovery was classified as complete (recovery to within 20% of pre-AKI serum creatinine level), 5, 6 partial (recovery to within 30% of pre-AKI serum creatinine value) 7 or "non-recovery" (no decline in serum creatinine or a decline not reaching the "within 30% of baseline value" threshold).
Statistical Analyses
Statistical analyses were conducted at the Coordinating Center using SAS software, version 9.4 (SAS Institute Inc). Baseline characteristics were compared among participants who did and did not have AKI during the trial, with the use of Student's t-test or the Wilcoxon rank sum test for continuous variables, and the chi 2 test for discrete or categorical variables. Continuous variables are presented as either the mean ± standard deviation (SD) if normally distributed or the median (25 th -75 th percentile) if not normally distributed.
hazards regression, with two-sided tests at the 5% level of significance, with stratification by clinical site.
An assessment for non-proportionality of hazards was made with the addition of the interaction between log (time) and the intervention. 8 Follow-up time was censored at the time of the final event ascertainment. Interactions between the treatment effect and prespecified subgroups were assessed using a likelihood ratio test for interaction. Baseline variables thought to be related to the time to development of AKI were assessed first in univariate models, and then added as a group to the primary analysis model.
In exploratory analyses, participants with multiple AKI events were analyzed according to data obtained at the first occurrence of AKI, to determine if these variables were predictive of recurrence. These exploratory analyses used time from first episode of AKI to first recurrence, with censoring time set at the participant's last visit. The association of AKI events with primary and secondary end points was evaluated using the Cox proportional hazards model, with a time-varying covariate for the first AKI episode.
RESULTS

Overview
The SPRINT cohort consists of 9361 participants who were followed up for a mean of 3.26 years before the BP intervention was stopped early on August 20, 2015, after the NIH accepted the recommendation of the Data and Safety Monitoring Board due to benefit in the intensive arm on the primary outcome ( Figure 1 ). 2 This study reports on AKI events occurring through August 20, 2015.
Incidence and Correlates of Adjudicated AKI events
There were 348 AKI events in 288 (3.0%) participants. Baseline characteristics of the study participants, stratified by the presence or absence of at least one AKI event, are shown in Table 1 . Baseline characteristics associated with the time to development of AKI included age 75 years or older, male sex, chronic kidney disease at trial entry, higher urine ACR, presence of CVD, higher Framingham risk score and, in at least one treatment group, also race/ethnicity, smoking status and systolic and/or diastolic BP. Of the 288 participants with an AKI event, 248 (86.1%) had a single AKI event during the course of the trial, 30 (10.4%) had two events, 5 (1.7%) had 3 events and 5 (1.7%) had 4 or more events. AKI events were typically mild, as AKI stage 1 was the most common AKI stage. Based on modified KDIGO criteria, the number of AKI events in the intensive versus standard arm by KDIGO stage was 128 (58.5%) vs. 81 (62.8%) in stage 1, 42 (19.2%) vs 18 (14.0%) in stage 2 and 42 (19.2%) vs. 25 (19.4%) in stage 3 (p=0.5 for comparison of stages of AKI by randomized arm; AKI events by CKD cohort in Table 2 ). Dialysis was required infrequently by participants in the intensive (n=8) and standard (n=6) arms (Table 3 ) and end-stage renal disease subsequently developed in 2 intensive-arm and 3 standard-arm participants. No participant underwent kidney transplantation for irreversible AKI.
Etiology and Risk Factors of AKI Events
The most common proximate cause of AKI events in both arms of the trial was dehydration and/or intravascular volume depletion, followed by hypotension (Table 3 ). In both the CKD and non-CKD cohort, 10.0% of the cases of AKI in the intensive arm and 2.3% of cases in the standard arm were thought to be secondary to the intervention. By multivariable analysis, risk factors for time to development of an AKI event included older age, non-white race, lower baseline eGFR, and presence of CVD at baseline ( Table 4 ).
Effects of Intensive BP Lowering on AKI by Prespecified Subgroups
There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%). The hazard ratio (HR) for AKI in the intensive versus standard arms was 1.64 (95% CI, 1.30-2.10; Figure 2 ). The effects of the intervention on the rate of AKI were consistent across the prespecified subgroups (baseline CVD, baseline CKD, sex, race, age, and baseline SBP) ( Figure 3 ). There were no significant interactions between treatment and subgroup (p values range, 0.06-0.9).
Post-AKI events
Among participants with sufficient data to determine recovery, complete or partial resolution of AKI was seen for 169 (90.4%) and 9 (4.8%) of the 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of the 99 AKI events in the standard arm, respectively. Only 14 (5.6%) events required dialysis for the treatment of AKI and 50% of these participants subsequently became dialysis independent.
Exploratory analyses were conducted to examine the risk of events following AKI. When including first AKI event as a time-varying covariate in a Cox model accounting for randomized group, AKI events were found to be associated with higher risks of both the primary SPRINT outcome (501 events in the no AKI group [5.5%] vs. 61 events in the AKI group [21.2%]; HR, 2.0; 95% CI, 1.2-3.1; p = 0.004) as well as death from any cause (320 events in the no AKI group [3.5%] vs. 45 events in the AKI group [15.6%]; HR, 5.6; 95% CI, 4.0-7.8; p <0.001). Causes of death by randomized arm are shown in Table 5 .
DISCUSSION
In SPRINT, participants randomized to the intensive BP-lowering arm had significantly lower rates of the trial's primary composite end point, as well as lower rates of death and no difference in the total number of SAEs compared to participants randomized to the standard arm. These benefits were offset by a subset of SAEs that were more common in participants in the intensive treatment arm, including AKI. Of those participants who developed AKI in either arm of the trial, AKI stage, as assessed by modified KDIGO criteria, was in the lowest stage of severity for more than 50% of AKI events. AKI events were mainly attributed to volume depletion and in about 90% of persons in either study arm resulted in complete or partial recovery of kidney function. The need for dialytic therapy for the treatment of AKI was exceedingly rare (0.15%). Moreover, the rate of development of AKI in SPRINT was steady throughout the trial; specifically, AKI was not more common during the initial year, when participants generally experienced the most active titration of anti-hypertensive medications ( Figure 2 ). We hypothesize that the increased frequency of AKI events in the intensive arm may have been due to the lower baseline SBP that resulted in an increased risk of the BP falling below the autoregulatory threshold for kidney perfusion when a volume depleting illness and/or hypotension occurred.
Episodes of AKI, including those not severe enough to require dialysis, have consistently been shown to associate with an increased risk of in-hospital mortality. [9] [10] [11] Indeed, in this trial, we found that AKI was associated with an increased risk of the primary SPRINT outcome and of death from any cause. Moreover, AKI has the potential to cause significant morbidity, as AKI can contribute to progressive CKD and, in some instances, end-stage kidney disease. [12] [13] [14] Risk factors for AKI include the presence of CKD and older age, subgroups that were specifically recruited into SPRINT. Thus, during protocol development for SPRINT, it was recognized that the acute decrease in eGFR that had been seen in previous hypertension trials 15, 16 could adversely affect kidney function in SPRINT participants, both on a long-term basis, and also by increasing the risk of AKI events. The paucity of AKI events in SPRINT that resulted in longer-term deterioration of kidney function allays this latter concern. In addition, although participants in the intensive arm had an increased risk of AKI events, participants in the intensive arm still had a reduced risk of the primary SPRINT outcome and all-cause mortality compared to those in the standard arm. 2 These findings help in interpreting the risk-benefit ratio of the SPRINT results and are important to consider when developing clinical guidelines for the management of hypertension.
Comparison of the SPRINT AKI results with other hypertension trials is difficult for several reasons. First, a minority of hypertension trials provide information on the incidence of AKI. 17 Second, persons with CKD, a major risk factor for AKI, have often been excluded from hypertension trials. 18 Furthermore, there is no consensus regarding how to define recovery of kidney function after AKI; a recent meta-analysis demonstrated that there was a broad range of definitions including variability in the timing of post-AKI creatinine measures and in the thresholds used for recovery based on serum creatinine concentrations. 19 We chose to report recovery of kidney function using two different definitions. United Kingdom guidelines adopted a return of serum creatinine to within 20% of baseline as a definition of recovery; the Program to Improve Care in Acute Renal Disease (PICARD) used the same definition. 5, 6 Other investigators proposed a threshold of recovery to within 30% of the baseline serum creatinine concentration and cite an increased risk of CKD if recovery does not occur. 7 There are several strengths of these analyses, including the large sample size, inclusion of participants with risk factors for AKI, including CKD at baseline and older age, wide separation between achieved BPs in the trial arms, and capture of major diagnoses from virtually all hospitalizations. There are also important limitations to these analyses. First, serum creatinine data-in hospital and thereafter-were relatively sparse and collected based on the trial protocol (monthly for 3 months, then biannually), rather than based on clinical indications. In other words, post-discharge serum creatinine determinations were not uniformly obtained. Second, site staff were unblinded and could have looked more carefully for AKI events in records of participants randomized to the arm with intensive BP lowering.
Third, although adjudicators were blinded to treatment assignment, in some cases they may have been able to infer the treatment assigned to individual participants. Fourth, AKI events that were managed in the outpatient setting were not captured in this analysis; however, it is likely that these events were not severe enough to warrant either a hospital admission or evaluation in an ED. Note that data on changes in kidney function based on SPRINT laboratory data only will be the subject of two additional studies. Thus, the AKI prevalence reported herein is likely an underestimation of the true AKI incidence in the trial, but does capture all AKI events of sufficient severity to be associated with a hospitalization. Finally, these results are generalizable only to the study population, and thus should be extrapolated cautiously to other patient populations, including those with diabetes mellitus or polycystic kidney disease, persons at low risk for cardiovascular events, and institutionalized patients.
In sum, more intensive BP lowering in persons with hypertension at high risk for CVD resulted in an increase in the risk of AKI, although episodes of AKI were generally mild and largely reversible. Patients and physicians who undertake more intensive BP-lowering strategies should be alert for the risk of AKI, particularly among older patients and patients with CKD. However, for patients thought to benefit in terms of CVD prevention, fear of AKI should not preclude an intensive BP-lowering strategy. Forest Plot of Acute Kidney Injury. The dashed vertical line represents the hazard ratio for the overall study population. The box sizes are proportional to the precision of the estimates (with larger boxes indicating a greater degree of precision). The subgroup of no previous chronic kidney disease (CKD) includes some participants with unknown CKD status at baseline. Black race includes Hispanic black and black as part of a multiracial identification. Table 5 Causes of death for 45 participants with any AKI event who died
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